No Data
No Data
Nomura Adjusts Aier Eye Hospital's Price Target to 15.35 Yuan From 22.14 Yuan, Keeps at Buy
04:55 AM EDT, 04/26/2024 (MT Newswires) -- Nomura Adjusts Aier Eye Hospital's Price Target to 15.35 Yuan From 22.14 Yuan, Keeps at Buy Price (RMB): ¥12.63, Change: ¥+0.39, Percent Change: +3.19%
Declining Stock and Solid Fundamentals: Is The Market Wrong About Aier Eye Hospital Group Co., Ltd. (SZSE:300015)?
With its stock down 13% over the past three months, it is easy to disregard Aier Eye Hospital Group (SZSE:300015). However, a closer look at its sound financials might cause you to think again. Give
Aier Eye Hospital Group Co., Ltd. (SZSE:300015) Investors Are Less Pessimistic Than Expected
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 32x, you may consider Aier Eye Hospital Group Co., Ltd. (SZSE:300015) as a stock to potentially avoid with it
Aier Ophthalmology (300015.SZ): Currently, it is the largest ophthalmology chain medical group in China. Many hospitals are gradually taking up the largest market share in the region in terms of outpatient visits, surgery volume, and revenue
Gelonghui, March 15 | Aier Ophthalmology (300015.SZ) said on the investor interactive platform that the company is currently the largest ophthalmology medical chain in China, and many hospitals are gradually occupying the largest market share in the region in terms of outpatient visits, surgery volume, and revenue. After years of development, the scale effect of the company is becoming more and more obvious, and its core competitiveness in terms of technology, brand, service, scale, talent, scientific research, and management has been further strengthened. China has a huge population base, and the penetration rate of ophthalmology specialists in all subdivisions is very low. As Chinese residents continue to increase their awareness of eye health and their income levels increase, the potential demand for ophthalmology care will continue
Aier Ophthalmology (300015.SZ): The optometry business is a complete system from prevention, control to treatment. In addition to low-concentration atropine, there are also various myopia prevention and control products such as OK lenses, defocused soft l
On March 14, Ge Longhui Ophthalmology (300015.SZ) said on the investor interactive platform that the company is closely following the progress and development of ophthalmology diagnosis and treatment technology at home and abroad. In terms of the prevention and control of myopia among young people, the company has obtained the “Medical Institution Formulation License”, its 0.05% atropine eye drops have obtained relevant approval, and the product has entered clinical practice. At this stage, the incidence of myopia is high, and there is a clear trend of getting younger and more advanced. The task of preventing and controlling myopia among young people is very heavy, and there is a growing demand for the use of prevention and control products. The company's optometry business is a complete system from prevention, control to treatment. In addition to low-concentration atropine, it also has OK lenses and defocus
Why You Should Care About Aier Eye Hospital Group's (SZSE:300015) Strong Returns On Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term? Typically, we'll want to notice a trend of growing return on capital employed (ROCE)
No Data